ABBOTT INDIA LIMITED

🇮🇳India
Ownership
Private
Established
1888-01-01
Employees
73K
Market Cap
$7.5B
Website
http://www.abbott.com
Clinical Trials
Related News

Early Access Program of the Safety of Human Anti-TNF Monoclonal Antibody Adalimumab in Subjects With Active Rheumatoid Arthritis

First Posted Date
2008-04-01
Last Posted Date
2008-04-14
Lead Sponsor
Abbott
Registration Number
NCT00650026

Study of Adalimumab Administered as Subcutaneous Injections in Adult Chinese Rheumatoid Arthritis Subjects Treated With Methotrexate

First Posted Date
2008-04-01
Last Posted Date
2008-04-01
Lead Sponsor
Abbott
Target Recruit Count
47
Registration Number
NCT00647920

Assessment of the Effect of Adalimumab on Response to Influenza Virus and Pneumococcal Vaccines in Subjects With Rheumatoid Arthritis

First Posted Date
2008-04-01
Last Posted Date
2008-04-01
Lead Sponsor
Abbott
Target Recruit Count
226
Registration Number
NCT00649922

Open Label Study to Assess Efficacy and Safety of the Fully Human Anti-TNF-Alpha Monoclonal Antibody Adalimumab

First Posted Date
2008-04-01
Last Posted Date
2008-04-01
Lead Sponsor
Abbott
Registration Number
NCT00650390

Study of the Human Anti-TNF Monoclonal Antibody in Patients With Active Rheumatoid Arthritis

First Posted Date
2008-04-01
Last Posted Date
2008-04-01
Lead Sponsor
Abbott
Registration Number
NCT00649545

Study Comparing 80 mg of Adalimumab With Placebo, and Demonstrating the Non-inferiority of Monthly 80 mg Adalimumab Dosing Compared With 40 mg Adalimumab Every Other Week Dosing

Phase 3
Completed
Conditions
Rheumatoid Arthritis
Interventions
Drug: Placebo
Drug: adalimumab
First Posted Date
2008-03-31
Last Posted Date
2011-04-11
Lead Sponsor
Abbott
Target Recruit Count
420
Registration Number
NCT00647270

Adalimumab in Adult Japanese Subjects With Psoriasis

Phase 2
Completed
Conditions
Psoriasis
Interventions
Biological: adalimumab
First Posted Date
2008-03-31
Last Posted Date
2011-04-08
Lead Sponsor
Abbott
Target Recruit Count
147
Registration Number
NCT00647400
Locations
🇯🇵

Site Ref # / Investigator 5495, Hiroshima-city, Japan

🇯🇵

Site Ref # / Investigator 5491, Bunkyo-ku, Japan

🇯🇵

Site Ref # / Investigator 5429, Chiyoda-ku, Japan

and more 61 locations

A Study of Adalimumab in Adult Japanese Subjects With Rheumatoid Arthritis

First Posted Date
2008-03-31
Last Posted Date
2008-03-31
Lead Sponsor
Abbott
Target Recruit Count
352
Registration Number
NCT00647491

Paricalcitol Injection Phase II Trial

Phase 2
Completed
Conditions
Chronic Kidney Disease
Interventions
Drug: paricalcitol
First Posted Date
2008-03-31
Last Posted Date
2008-03-31
Lead Sponsor
Abbott
Target Recruit Count
25
Registration Number
NCT00646932

Extension Study of Two Dosing Schedules of Adalimumab in Subjects With Moderate to Severe Chronic Plaque Psoriasis

Phase 2
Completed
Conditions
Psoriasis
Interventions
Drug: adalimumab
Drug: placebo for adalimumab
First Posted Date
2008-03-28
Last Posted Date
2008-03-28
Lead Sponsor
Abbott
Target Recruit Count
32
Registration Number
NCT00645892
© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy